



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/626,772	07/25/2003	Kazutomo Inoue	0020-5157P	1689
2292	7590 02/22/2006		EXAMINER	
BIRCH STEWART KOLASCH & BIRCH			CROUCH, DEBORAH	
PO BOX 747 FALLS CHURCH, VA 22040-0747		ART UNIT	PAPER NUMBER	
	,		1632	
			DATE MAILED: 02/22/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No. Applicant(s)					
Office Astion Commence		10/626,772	INOUE ET AL.				
	Office Action Summary	Examiner	Art Unit				
<u></u> .		Deborah Crouch, Ph.D.	1632				
Period fo	The MAILING DATE of this communication aport Reply	pears on the cover sheet with the	correspondence address				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL CHEVER IS LONGER, FROM THE MAILING Densions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statuted the patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION  136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	timely filed  m the mailing date of this communication.  IED (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on						
2a)	This action is <b>FINAL</b> . 2b) Thi						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
4) 🖂	Claim(s) 1-14 is/are pending in the application	٦.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
_	Claim(s) is/are allowed.						
	6) Claim(s) is/are rejected.						
7)	7) Claim(s) is/are objected to.						
8)⊠	B)⊠ Claim(s) <u>1-14</u> are subject to restriction and/or election requirement.						
Applicat	on Papers						
9)	The specification is objected to by the Examin	er.					
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correct	ction is required if the drawing(s) is o	bjected to. See 37 CFR 1.121(d).				
11)	The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.				
Priority ι	ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreig ☐ All b)☐ Some * c)☐ None of:	n priority under 35 U.S.C. § 119(	a)-(d) or (f).				
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the price	ority documents have been received	ed in this National Stage				
	application from the International Burea	• • • • • • • • • • • • • • • • • • • •					
* 5	See the attached detailed Office action for a lis	t of the certified copies not receive	ed.				
Attachmen							
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summar Paper No(s)/Mail I	• •				
3) 🔲 Infon	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 r No(s)/Mail Date		Patent Application (PTO-152)				

Art Unit: 1632

Application/Control Number: 10/626,772

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 5, 6, 10, 12 and 13, drawn to a method of inducing differentiation of mammalian embryonic stem cells into functioning pancreatic cells, pancreatic cells, and methods of using the cells to treat disorders of pancreatic function classified in at least class 435, subclass 377.

II. Claims 7, 8, 11 and 14 drawn to drawn to a method of inducing differentiation of mammalian embryonic stem cells into functioning nerve-like cells, pancreatic cells, and methods of using the cells to treat disorders in nerve function classified in at least class 435, subclass 377.

Claims 1-4 and 9 link(s) inventions I and II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 1-4 and 9. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Inventions I and II are mutually exclusive and independent inventions. As evidenced by the claimed subject matter, the methods of differentiating pancreatic islet-like cells and nerve-like cells require materially different and separate media. Further, neither the

Art Unit: 1632

methods nor cells of invention I is needed to implement the methods or cells of invention II, or vice-versa.

Because these inventions are distinct for the reasons given above and have acquired because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Any search would not be co-extensive.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah Crouch, Ph.D. whose telephone number is 571-272-0727. The examiner can normally be reached on M-Fri, 7:30 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1632

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Deborah Crouch, Ph.D. Primary Examiner

Art Unit 1632

February 20, 2006